Mar 30, 2022 09:06PM moth wrote:
Oncotype uses a different method to determine hormone status than IHC. It is said that if there's a discrepancy, you should go with the IHC. But, in some cases - like mine - it leads to a whole review of IHC status. My 2017 initial IHC from biopsy was 10% faint ER+/PR-/HER2-. Oncotype came back & said I was triple neg. My biopsy sample & my tumor sample did the rounds among pathologists here for 2nd opinions & eventually they coded it as negative as well.
I believe Oncotype factors the strength of the ER positivity into the recurrence score. Not sure how well the search function is doing right now but Beesie did a number of posts about this .. I think she's on board break while the board is being revamped atm
Initial dx at 50. Seriously?? “Sometimes the future changes quickly and completely and we’re left with only the choice of what to do next." blog: Never Tell Me the OddsDx 12/2017, IDC, Left, 1cm, Stage IA, Grade 3, 0/5 nodes, ER-/PR-, HER2- Surgery 12/12/2017 Lumpectomy; Lumpectomy (Left); Lymph node removal Chemotherapy 2/14/2018 AC + T (Taxol) Radiation Therapy 8/13/2018 Whole breast: Breast Dx 2/2020, IDC, Left, Stage IV, metastasized to liver/lungs, Grade 3, ER-/PR-, HER2- Chemotherapy 3/18/2020 Taxol (paclitaxel) Immunotherapy 3/19/2020 Tecentriq (atezolizumab) Chemotherapy 11/26/2020 Abraxane (albumin-bound or nab-paclitaxel) Radiation Therapy 12/9/2020 External Hormonal Therapy 12/16/2020 Femara (letrozole) Radiation Therapy 3/3/2021 External Local Metastases 3/3/2021 Radiation therapy: Bone Targeted Therapy 1/1/2022 Trodelvy (sacituzumab govitecan-hziy) Chemotherapy 6/1/2022 Other